While chemerin1 and chemerin2 expression were not evaluated, CCRL2 mRNA and protein levels were reported to be increased in prostate cancer PC3 cells, and CCRL2 expression increased in prostate cancer tissues versus prostate tissues from patients with benign prostatic hyperplasia [124]. This evidence concerns the gene CCRL2 and benign prostatic hyperplasia.